Lung Cancer Therapy: New Strategies & Treatments
- What: A resurgence of Mpox (formerly known as monkeypox) is occurring globally, with a notable increase in cases among individuals with HIV.
- Where: Cases have been reported across multiple continents, including North America, Europe, and Africa, with concentrated outbreaks in specific urban centers.
- When: The resurgence began gaining momentum in early 2025, with a meaningful increase observed in the summer of 2025 (data as of August 27, 2025).
“`html
The Rise of Mpox in 2025: A Complete Update
Table of Contents
What is Mpox and Why is it Resurging?
Mpox is a viral infection historically endemic to parts of Central and West Africa. The virus, belonging to the orthopoxvirus family, causes a rash that can resemble chickenpox or syphilis, accompanied by fever, headache, muscle aches, and swollen lymph nodes. While typically self-limiting, Mpox can lead to severe complications, especially in individuals with weakened immune systems.
The global outbreak in 2022 brought Mpox to the forefront of public health concerns. While initial control measures appeared accomplished, a resurgence in 2025 indicates the virus hasn’t been eradicated and continues to pose a threat. Several factors likely contribute to this renewed spread, including waning immunity from prior infection or vaccination, changes in viral transmission patterns, and perhaps, viral evolution.
Key Findings from Recent Data (August 2025)
Recent data published in the New England Journal of Medicine (August 21/28,2025) reveals a concerning trend: a disproportionate number of cases are occurring among individuals living with HIV. A retrospective cohort study conducted in multiple countries showed that individuals with untreated HIV had a considerably higher risk of severe Mpox illness requiring hospitalization compared to those without HIV or those with well-controlled HIV infection.
The study analyzed data from over 5000 confirmed Mpox cases. It found that approximately 38% of hospitalized patients were living with HIV, a figure substantially higher than thier portrayal in the general population. Furthermore, individuals with a CD4 count below 200 cells per cubic millimeter experienced the most severe outcomes, including secondary bacterial infections and prolonged hospitalization.
| Characteristic | Mpox Cases (overall) | Hospitalized Mpox Cases |
|---|---|---|
| Total Cases (n) | 5,234 | 457 |
| Median Age (years) | 35 | 42 |
| Percentage with HIV | 12% | 38% |
| Percentage with CD4 < 200 | 3% | 15% (among those with HIV) |
Transmission and Symptoms
Mpox spreads through close,personal contact with the rash,scabs,or body fluids of an infected person.It can also be transmitted through respiratory secretions during prolonged face-to-face contact, and potentially through contaminated objects (fomites).Sexual contact has been identified as a significant mode of transmission in recent outbreaks, but Mpox is not exclusively a sexually transmitted infection.
Symptoms typically appear 5-21 days after exposure.The initial phase often involves fever, headache, muscle aches, and swollen lymph nodes. Within 1-3 days, a rash develops, starting as flat, red spots that progress to fluid-filled blisters. These blisters eventually scab over and fall off, a process that can take several weeks. The rash can appear anywhere on the body, including the face, hands, feet, and genitals.